- Home
- / Monte Rosa Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Monte Rosa Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$9.4
2024-10-29
Market Capitalization
$575.1 M
2024-10-29
Revenue
$123.7 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 75.6M | 123.7M | |||
| General and administrative expense | 15.7M | 27.3M | 32.0M | 35.2M | 36.4M |
| Operating expense total | 112.4M | 156.7M | 177.9M | ||
| EBIT | (72.9M) | (112.4M) | (143.3M) | (81.1M) | (54.2M) |
| EBIT margin, % | -107.3% | -43.8% | |||
| Interest expense | 46.0K | 3.8M | 9.3M | 10.6M | 12.9M |
| Pre tax profit | (9.9M) | (17.2M) | (135.0M) | (70.1M) | (39.7M) |
| Income tax expense | 338.0K | 2.6M | (1.1M) | ||
| Net Income | (74.0M) | (108.5M) | (135.4M) | (72.7M) | (38.6M) |